IPO Observation: No Commercial Sales, Continuous Losses Face Registration "Difficulty"
As early as January 11, 2023, Guangzhou Biobeet Pharmaceutical Co., Ltd. (hereinafter referred to as \"Biobeet\") had passed the review of its IPO application through the sci-tech board.